2026 Dyslipidemia Guideline Adds 25 Million Statin Candidates
This NHANES modeling study quantifies how the 2026 ACC/AHA dyslipidemia guideline expands statin eligibility and exposes a large treatment-intensification gap that anticoagulation and cardiology pharmacists will help manage.
📅 Journal publication: Jul 29, 2026·Last updated: Aug 23, 2026
2026 guidelines expand statin eligibility for millions of adults.
The updated 2026 dyslipidemia guidelines significantly increase the number of adults eligible for lipid-lowering therapy (LLT), potentially impacting clinical management at a population level. Under the 2026 guideline, 40.5% of adults are eligible for LLT compared to 25.7% under the 2018 guideline, affecting an additional 24.5 million adults. The 2026 guidelines will lead to increased statin therapy initiation and intensification to meet new LDL-C goals, requiring adjustments in current treatment practices. New guidelines significantly expand LLT eligibility, prompting increased statin use.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Citation:Sayed A, Peterson ED, Navar AM Implications of the 2026 Versus 2018 ACC/AHA Multisociety Dyslipidemia Guidelines on the Clinical Care of U.S. Adults. Journal of the American College of Cardiology. 2026. doi:10.1016/j.jacc.2026.06.037
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.